Table 1.
Clinical characteristics of patients in group 3: Unclassified inflammatory demyelinating disorders. The final AQP4-IgG result was considered positive when one or more tests were positive. Patient 6 and 11 were reclassified as NMO rather than multiple sclerosis, and were withdrawn from IFN-beta.
| Patient no. | Sex/Age at onset | ON episodes | Myelitis episodes(MRI longest lesion length) | Brain lesions (Y/N); fulfilled Barkhof criteria (Y/N) | AQP-4-IgG serostatus | Therapy pre-testing | |||
|---|---|---|---|---|---|---|---|---|---|
| IFA (Negative<120) | ELISA*(Negative <5IU/ML) | CBA* | FINAL RESULT | ||||||
| 1 | F/50 | 8 | 12 (<3 segs) | Yes; No | − | − | + | Positive | Azathioprine |
| 2 | F/47 | 0 | 2 (<3 segs) | Yes; No | − | 6.4 | + | Positive | Azathioprine |
| 3 | F/55 | 2 | 1(<3 segs) | Yes; No | − | − | − | Negative | IFN-β |
| 4 | F/37 | 3 | 1 (<3 segs) | Yes; No | 3840 | 126.0 | + | Positive | Azathioprine |
| 5 | F/51 | 10 | 7 (>3 segs) | Yes; Yes | − | − | + | Positive | Mycophenolate mofetil |
| 6 | F/48 | 1 | 7 (>3 segs) | Yes; Yes | 3840 | 39.3 | + | Positive | IFN-β (no benefit); azathioprine plus prednisolone (long term remission) |
| 7 | F/21 | 0 | 1 (>3 segs) | Yes; Yes | − | − | − | Negative | Azathioprine |
| 8 | F/30 | 0 | 1 (>3 segs) | No | 240 | 109 | + | Positive | Prednisolone |
| 9 | F/63 | 0 | 1 (>3 segs) | Yes; Yes | − | 9.6 | + | Positive | None |
| 10 | F/30 | 0 | 8 (>3 segs) | No | 240 | 36.7 | + | Positive | Mycophenolate mofetil |
| 11 | F/40 | 0 | 2 (>3 segs) | Yes; Yes | − | 16.6 | + | Positive | IFN-β |
| 12 | F/55 | 0 | 3 (>3 segs) | No | − | 7.0 | + | Positive | Azathioprine |
| 13 | F/25 | 0 | 3 (>3 segs) | Yes; Yes | − | 15.1 | + | Positive | Azathioprine plus prednisolone |
| 14 | F/34 | 2 | 0 | No | − | − | − | Negative | IFN-β |
| 15 | F/28 | 3 | 0 | No | 3840 | >160 | + | Positive | None |
| 16 | F/56 | 3 | 0 | No | − | 9.7 | + | Positive | Cyclophosphamide |
*
AQP4 ELISA kit from RSR/Kronus Ltd. and CBA slides from Euroimmun.